HEK293 Cells Maintain Genomic Stability Despite Diverse Cultivation Histories

Human embryonic kidney (HEK293) cells are widely used in biopharmaceutical manufacturing, with a recent surge particularly in recombinant adeno-associated virus production. Despite their industrial relevance, comprehensive data on their genomic background and stability has remained limited. To address this gap, a recent study systematically analyzed the genetic landscape of various HEK293 cell lines, investigating their response to cultivation conditions, clonal selection, genetic manipulation, and time in culture.

The research involved adapting adherent HEK293 cells to suspension growth using different serum-free media. Whole-genome sequences from these cell lines were analyzed together with previously published data from additional variants in common use. Smesnik, the lead author, notes in the paper: "All data sets were aligned against the human reference genome, enabling the assessment of genome stability by evaluation of variants and revealing a conserved genetic core across all lines, regardless of cultivation history or phenotypic divergence." This alignment provided the basis for a detailed assessment of genomic stability. The study observed that the distribution of structural variants and single nucleotide polymorphisms indicated a gradual accumulation of mutations over time in culture, rather than abrupt shifts in response to environmental changes. Importantly, the integrated adenoviral genes remained highly conserved with respect to copy number, integration site, and sequence integrity.

Further analysis of the functional implications of conserved core mutations identified an enrichment in genes related to cellular structure, morphology, and cellular connectivity. These findings provide insight into the genomic evolution of HEK293 cells and offer a foundation for further multi-omics studies. Ultimately, this research aims to facilitate the optimization of HEK293 cells, enhancing their reliability and efficiency for applications in biopharmaceutical production.